iBio (IBIO) Asset Writedowns and Impairment (2018 - 2026)
iBio (IBIO) posted quarterly Asset Writedowns and Impairment of $4.9 million for Q1 2026, up 59.29% quarter-over-quarter from $3.1 million in Q4 2023.
iBio (IBIO) Asset Writedowns and Impairment (2018 - 2026) Analysis & Trends
iBio (IBIO) has reported Asset Writedowns and Impairment for 6 consecutive years, with $4.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $8.0 million (up 136.41% YoY), while the FY2024 annual figure was $3.1 million, down 36.93% from the prior year.
- Asset Writedowns and Impairment rose to $4.9 million in Q1 2026 per IBIO's latest filing, from $3.1 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $4.9 million in Q1 2026 and bottomed at -$17.1 million in Q1 2023.
- Historically, Asset Writedowns and Impairment has averaged -$1.1 million across 3 years, with a median of $1.2 million in 2022.
- On a YoY basis, Asset Writedowns and Impairment climbed as much as 448.67% in 2023 and fell as far as 82.95% in 2023.
- iBio's Asset Writedowns and Impairment stood at $565000.0 in 2022, then surged by 448.67% to $3.1 million in 2023, then soared by 59.29% to $4.9 million in 2026.
- Business Quant data shows IBIO's Asset Writedowns and Impairment at $4.9 million in Q1 2026, $3.1 million in Q4 2023, and $300000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.94 Mn |
| Mar 31, 2026 | 4.94 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Jun 30, 2023 | 300,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Mar 31, 2023 | -17.08 Mn |
| Mar 31, 2023 | -17.08 Mn |
| Dec 31, 2022 | 565,000.00 |
| Dec 31, 2022 | 565,000.00 |
| Jun 30, 2022 | 1.76 Mn |
| Jun 30, 2022 | 1.76 Mn |
| Mar 31, 2021 | 300,000.00 |
| Mar 31, 2021 | 300,000.00 |
| Dec 31, 2020 | 497,000.00 |
| Dec 31, 2020 | 497,000.00 |
| Jun 30, 2018 | 61,000.00 |
| Jun 30, 2018 | 61,000.00 |